{"id":"W4387950784","doi":"10.2217/fon-2023-0526","title":"TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Oncology; Olaparib; Placebo; Androgen deprivation therapy; Clinical trial; Androgen receptor; Cancer; Poly ADP ribose polymerase; Gene; Pathology; Biology; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001755492,0.0002432696,0.001193719,0.0003122034,0.00006093897,0.000008953164,0.00009997907,0.0002071892,0.0002202963],"category_scores_gemma":[0.0001860126,0.0002063789,0.0001384341,0.0008899193,0.0002003897,0.00009257857,0.00004909299,0.0006165329,0.0000296662],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004916751,"about_ca_system_score_gemma":0.001951913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003168575,"about_ca_topic_score_gemma":0.002285446,"domain_scores_codex":[0.9963118,0.0009024829,0.001447469,0.0005424372,0.0004015002,0.0003943516],"domain_scores_gemma":[0.9982294,0.0004524892,0.000560238,0.0003442137,0.0002601577,0.0001535178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8323759,0.02042129,0.00804625,0.0004330573,0.001217372,0.004172592,0.03046013,0.0007755735,0.008246495,0.0003713613,0.01831354,0.0751664],"study_design_scores_gemma":[0.8883721,0.03797112,0.01049593,0.0001900557,0.0003196014,0.00009138611,0.01528689,0.0008302326,0.002102367,0.0001523455,0.04385009,0.0003379361],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8893812,0.0000211081,0.00001754627,0.001767884,0.001323693,0.1065766,0.00007450112,0.0000938415,0.0007435807],"genre_scores_gemma":[0.8358145,0.00004558908,0.0003233333,0.0005839883,0.001889677,0.160578,0.00008945276,0.00004885143,0.0006265579],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07482847,"threshold_uncertainty_score":0.8415886,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1308447482002217,"score_gpt":0.5230714336123913,"score_spread":0.3922266854121696,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}